News Story: Full Text
Sponsored By
Cedars-Sinai Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website


Having sold its corporate self, Tocagen auctions off scientific platform to San Diego biotech


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 This is great news.   It looked like Tocagen's phase 3 clinical trial failed so they stopped development of the drug. However, there were some stunning successes in earlier trials and even in the failed trial there were some cases that were deemed a success.  However, the control group did a little better overall than the treatment group.

A new company purchased the drug and presumably will do further testing but this time targeted to those most likely to benefit from it!  

 


Posted on: 04/30/2020

Having sold its corporate self, Tocagen auctions off scientific platform to San Diego biotech

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740